Will Exelixis stock go up?

According to Danelfin AI, Exelixis has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (52.42%) is +1.60% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Exelixis stock?

The Exelixis target price is $48.79 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Exelixis stock right now?

Exelixis has today a Hold rating (AI Score 5/10), according to Danelfin AI. Its probability of beating the market in 3 months (52.42%) is +1.60% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Exelixis stock is a good buy .

Is Exelixis undervalued right now?

Based on analysts, the average price target downside for Exelixis is -9.62% (1Y). According to Danelfin AI, Exelixis has today an AI Score of 5/10 (Hold Rating).

What was the price range of Exelixis stock over the past 12 months?

The Exelixis stock price range over the past 12 months has been $34.54 - $54.77.

What is going on with Exelixis stock in the last 3 months?

The Exelixis stock performance in the last quarter has been +25.85%.

Does Exelixis offer dividend payments?

No, Exelixis does not currently pay dividends.

What is the current market capitalization of Exelixis?

Exelixis's market cap is $13.56B, as of 2026-07-02 08:00.

When is the next EXEL earnings report date?

EXEL will publish its next earnings report on 2026-05-05.

Exelixis Inc (EXEL) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

EXEL AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Valuation+3.23%
How the stock is priced relative to its fundamentals
Earnings Quality+0.24%
Stability and reliability of reported earnings
Size & Liquidity+0.22%
Company size and trading liquidity
Sentiment+0.07%
How analysts and the market view the stock

Momentum-1.60%
Direction and strength of recent price movements
Profitability-0.49%
Profitability and operating efficiency metrics
Volatility-0.07%
How much the stock price tends to fluctuate

EXEL probability advantage of beating the market (3M):

+1.60%

AI Score

Hold

Exelixis (EXEL) has an AI Score of 5/10 (Hold) because, according to an overall analysis, it has a probability advantage of +1.60% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of EXEL (52.42%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
EXEL probability advantage of beating the market (3M)+1.60%
EXEL probability of beating the market (3M)52.42%

EXEL probability advantage of beating the market (3M): +1.60%

The AI-powered overall analysis of Exelixis (EXEL) is based on the 28 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of EXEL:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+3.33%
Technical	Chart Pattern (120d)	figure_144	N/A	-1.03%
Technical	Chart Pattern (180d)	figure_193	N/A	-0.94%
Technical	Technicals Impact (Long Tail)	-	N/A	+0.92%
Sentiment	Industry (GICS)	Biotechnology	N/A	+0.72%
Technical	Chart Pattern (90d)	figure_85	N/A	-0.60%
Fundamental	Gross Margin	96.73		-0.49%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-0.47%
Fundamental	Tangible Shareholders' Equity	1.87K		+0.46%
Technical	Chart Pattern (60d)	figure_154	N/A	+0.46%
Fundamental	Upgrade to unlock			+0.41%
Sentiment	Upgrade to unlock			-0.41%
Technical	Upgrade to unlock			-0.40%
Sentiment	Upgrade to unlock			-0.38%
Technical	Upgrade to unlock			+0.37%

Rest of Alpha Signals: -0.35%

EXEL probability advantage of beating the market (3M)Total:+1.60%
EXEL AI Score

Significant changes Vs previous day

EXEL Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$53.98
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

EXEL Proven Hold Signal & Price Forecast

This is the price chart for EXEL from January 1, 2026 until today. The chart indicates, in yellow, the 65 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

EXEL Average Past Performance & Win Rate

Three months after its 1515 Hold signals since July 2026, EXEL had an average performance of xxxxxx and a xxxxxx Win rate (positive performance).

1515 Past EXEL Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+11.07%
Average Alpha				-1.81%
Win Rate (% Positive Perf.)				56.37%
% Positive Alpha				41.56%

EXEL Frequently Asked Questions

Will Exelixis stock go up?
According to Danelfin AI, Exelixis has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (52.42%) is +1.60% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Exelixis stock?
Is it a good time to buy, sell, or hold Exelixis stock right now?
Is Exelixis undervalued right now?
What was the price range of Exelixis stock over the past 12 months?
What is going on with Exelixis stock in the last 3 months?
Does Exelixis offer dividend payments?
What is the current market capitalization of Exelixis?
When is the next EXEL earnings report date?

Exelixis Inc Company Profile

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Sector:Health Care
Country:United States
Industry:Biotechnology
Address:1851 Harbor Bay Parkway, Alameda
Employees:1,077
Website:exelixis.com

Pros

Proprietary small molecule oncology drug discovery platform

Established commercialization capabilities for oncology products

Multiple approved indications for lead therapeutic asset

Physician and patient inertia with established oncology regimens

Intellectual property protection for key therapeutic compounds

Cons

Substantial capital expenditure for clinical trial programs

High clinical development failure rates for novel compounds

Revenue concentration in a single commercialized therapeutic

Intense competitive landscape in oncology therapeutics

Future patent cliff exposure for primary revenue driver

Company	AI Score	Compare
KPTIKaryopharm Therapeutics Inc
SNDXSyndax Pharmaceuticals Inc
ALXOALX Oncology Holdings Inc
SLXNSilexion Therapeutics Corp
BTAIBioXcel Therapeutics Inc

Company	AI Score	Compare
KPTIKaryopharm Therapeutics Inc
SNDXSyndax Pharmaceuticals Inc
ALXOALX Oncology Holdings Inc
SLXNSilexion Therapeutics Corp
BTAIBioXcel Therapeutics Inc

EXEL Stock AI Analysis

Exelixis Inc

EXEL Stock AI Analysis

Exelixis Inc

EXEL AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

AI Score Explanation

Generating AI Score explanation

AI Score Alpha Factors

Alpha Signals: What Drives the AI Score

EXEL probability advantage of beating the market (3M): +1.60%

EXEL Trading Parameters

EXEL Proven Hold Signal & Price Forecast

EXEL Average Past Performance & Win Rate

EXEL Frequently Asked Questions

Will Exelixis stock go up?

What is the target price for Exelixis stock?

Is it a good time to buy, sell, or hold Exelixis stock right now?

Is Exelixis undervalued right now?

What was the price range of Exelixis stock over the past 12 months?

What is going on with Exelixis stock in the last 3 months?

Does Exelixis offer dividend payments?

What is the current market capitalization of Exelixis?

When is the next EXEL earnings report date?

Exelixis Inc Company Profile

Pros

Cons

Pros

Cons

EXEL Company Profile Summary

EXEL Related Investment Themes

EXEL Related Stocks

EXEL Top 10 Industry Stocks

Biotechnology

EXEL Top 10 Sector Stocks

Health Care

EXEL Stock AI Analysis

Exelixis Inc

NASDAQ NMS - GLOBAL MARKET

Will Exelixis stock go up?

What is the target price for Exelixis stock?

Is it a good time to buy, sell, or hold Exelixis stock right now?

Is Exelixis undervalued right now?

What was the price range of Exelixis stock over the past 12 months?

What is going on with Exelixis stock in the last 3 months?

Does Exelixis offer dividend payments?

What is the current market capitalization of Exelixis?

When is the next EXEL earnings report date?

AI Score Explanation

Generating AI Score explanation

NASDAQ NMS - GLOBAL MARKET

Pros

Cons

EXEL Proven Hold Signal & Price Forecast